Formation Bio is a biotech headquartered in US. Over the past three years, Formation Bio has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (2 deals). The company currently has 1 active clinical trial, primarily in Dermatology.
Deals (12mo)
1
Active Trials
1
Top Modality
Small Molecules
Focus Area
Dermatology
Therapeutic areas and modalities where Formation Bio is most active based on deal history and clinical trial data.
Formation Bio has 1 active clinical trial across 1 development phase.
1
Phase 1
Use Solidus to benchmark upfront payments, milestones, and royalties for Dermatology assets — powered by data from 3,500+ real biopharma transactions.
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Formation Bio is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Formation Bio ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Formation Bio include Dermatology (1 deal and trial), and Neurology (1 deal and trial). In terms of modality, Formation Bio has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Formation Bio and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Formation Bio's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.